Page last updated: 2024-12-07

propargylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

propargylglycine: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID185909
CHEMBL ID1993296
SCHEMBL ID44356
MeSH IDM0053437

Synonyms (22)

Synonym
2-(prop-2-ynylamino)acetic acid
(2-propynylamino)acetic acid
AC-6385
nsc-692226
NCI60_033077
nsc692226
propargylglycine
propargyl-glycine
C4DA2C92-52F4-4D26-9A82-226D92723E5F
58160-95-5
acetic acid, 2-(prop-2-ynylamino)-
AKOS009210257
glycine,n-2-propyn-1-yl-
2-[(prop-2-yn-1-yl)amino]acetic acid
gtpl5247
SCHEMBL44356
CHEMBL1993296
DTXSID90206892
FT-0764746
Q27088455
2-[(prop-2-yn-1-yl)amino]aceticacid
EN300-97776

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" For toxic doses (5 microM), the loss of GSH preceded the onset of toxicity by six hr."( The role of glutathione in the toxicity of a novel cyanobacterial alkaloid cylindrospermopsin in cultured rat hepatocytes.
Ge, JL; Kong, SM; Lu, SC; Runnegar, MT; Zhong, YZ, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345185Human Cystathionine gamma-lyase (Hydrogen sulphide synthesis)2013British journal of pharmacology, Jun, Volume: 169, Issue:4
Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (256)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (11.33)18.7374
1990's34 (13.28)18.2507
2000's60 (23.44)29.6817
2010's123 (48.05)24.3611
2020's10 (3.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other262 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]